Stock Analiz

Alector, Inc. ALEC

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026

$2.54Market cap $378M
Open the interactive analysis →

Alector, Inc. (ALEC) is a healthcare company listed in the US with a market value of about $378M. In the twelve months to September 30, 2026 it had revenue of $173M and net income of $41M, a net margin of 23.9%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 7.3, 5-year revenue growth of -0% a year, a 5-year average ROIC of -74%.

About Alector

Alector is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2019. Revenue went from $4M in 2017 to $21M in 2025, growth of about 24.1% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 25% over three years (dilution for shareholders). It spends 585% of revenue on research and development.

Score: 0.8 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)7.3
Forward P/E—
P/FCF—
P/S2.2
P/B3.2
EV/EBITDA6.6
PEG—
Dividend yield0.00%
FCF yield-39.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-79.1%
Revenue growth (5 yrs, per year)-0.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-209.8%
ROIC (5-yr avg.)-74.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$173M$21M$101M$97M$134M$207M$21M$21M$28M$4M
Net income$41M-$143M-$119M-$130M-$133M-$36M-$190M-$105M-$52M-$32M
Free cash flow-$150M-$184M-$231M-$187M-$24M$295M-$172M-$115M$126M-$19M
EPS (diluted)$0.35$-1.39$-1.23$-1.56$-1.62$-0.45$-2.45$-1.71$-4.62$-3.55
Net margin23.9%-679.2%-118.4%-134.3%-99.8%-17.5%-901.6%-496.6%-188.8%-869.6%
ROIC—-183.4%-67.4%-69.3%-42.2%-8.5%-48.4%-37.2%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $4.42, 74% above the current price; targets range from $1.00 to $8.00; the consensus rating is “Buy”; expected EPS is $0.89 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Alector’s P/E ratio?

About 7.3, based on the last twelve months of diluted earnings per share.

Does Alector pay a dividend?

Not currently.

Is Alector a good stock to buy?

We do not give buy or sell advice. Alector scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.